Metraipolis › archive › dc_258b49b251fb

Paradoxical Efficacy With Rare Adverse Events: Sequential ALK Inhibitor Therapy in Lung Adenocarcinoma — Europe PMC PMID:42038652

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42038652
DOI
10.1002/ccr3.72469
License (as archived)
solo-consultazione
Archived
2026-11-03T07:14:36.293Z
SHA-256 of the archived text
0b5344ded5ee0d75ae2d248493045cb243a4f4e15e28e5495bf27a2560fbd52a
Stable URL of this page
https://metraipolis.com/documento/dc_258b49b251fb

How to cite

Paradoxical Efficacy With Rare Adverse Events: Sequential ALK Inhibitor Therapy in Lung Adenocarcinoma — Europe PMC PMID:42038652 — Europe PMC (en), https://europepmc.org/article/MED/42038652 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_258b49b251fb (Metraipolis archive dc_258b49b251fb, sha256 0b5344ded5ee0d75ae2d248493045cb243a4f4e15e28e5495bf27a2560fbd52a)
BibTeX
@misc{dc258b49b251fb,
  title = {Paradoxical Efficacy With Rare Adverse Events: Sequential ALK Inhibitor Therapy in Lung Adenocarcinoma — Europe PMC PMID:42038652},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42038652},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_258b49b251fb; sha256 0b5344ded5ee0d75ae2d248493045cb243a4f4e15e28e5495bf27a2560fbd52a},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42038652. Agents can read the archived copy with the MCP tool read_document.